In contrast, prostate cancers exhibit enhanced fatty acid oxidation (FAO) and increased expression of 2,4 dienoyl-CoA reductase 1 (DECR1), a rate-limiting enzyme in β-oxidation of PUFA, in malignant prostate tissues compared to nonmalignant tissues [93]. This evidence concerns the gene DECR1 and prostate cancer.